ORMP
Income statement / Annual
Last year (2024), Oramed Pharmaceuticals Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Oramed Pharmaceuticals Inc.'s net income was -$19.10 M.
See Oramed Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
08/31/2021 |
08/31/2020 |
08/31/2019 |
08/31/2018 |
08/31/2017 |
08/31/2016 |
08/31/2015 |
| Operating Revenue |
$0.00 |
$1.34 M |
$2.70 M |
$2.70 M |
$2.71 M |
$2.70 M |
$2.45 M |
$2.46 M |
$641.00 K |
$0.00 |
| Cost of Revenue |
$193.00 K
|
$0.00
|
$0.00
|
$0.00
|
$90.00 K
|
$90.00 K
|
$86.00 K
|
$187.00 K
|
$490.00 K
|
$0.00
|
| Gross Profit |
-$193.00 K
|
$1.34 M
|
$2.70 M
|
$2.70 M
|
$2.62 M
|
$2.61 M
|
$2.36 M
|
$2.27 M
|
$151.00 K
|
$0.00
|
| Gross Profit Ratio |
0
|
1
|
1
|
1
|
0.97
|
0.97
|
0.96
|
0.92
|
0.24
|
0
|
| Research and Development Expenses |
$6.32 M
|
$8.97 M
|
$27.64 M
|
$20.99 M
|
$10.24 M
|
$13.52 M
|
$11.98 M
|
$10.28 M
|
$7.71 M
|
$4.78 M
|
| General & Administrative Expenses |
$6.46 M
|
$8.43 M
|
$13.81 M
|
$5.94 M
|
$4.23 M
|
$3.72 M
|
$4.08 M
|
$2.76 M
|
$2.45 M
|
$2.60 M
|
| Selling & Marketing Expenses |
$0.00
|
-$287.00 K
|
$1.85 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.46 M
|
$8.14 M
|
$15.66 M
|
$5.94 M
|
$4.23 M
|
$3.72 M
|
$4.08 M
|
$2.76 M
|
$2.45 M
|
$2.60 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$12.78 M
|
$17.11 M
|
$43.30 M
|
$26.93 M
|
$14.47 M
|
$17.24 M
|
$16.06 M
|
$13.04 M
|
$10.16 M
|
$7.38 M
|
| Cost And Expenses |
$12.78 M
|
$17.11 M
|
$43.30 M
|
$26.93 M
|
$14.47 M
|
$17.33 M
|
$15.98 M
|
$13.23 M
|
$10.65 M
|
$7.38 M
|
| Interest Income |
$0.00
|
$8.03 M
|
$3.57 M
|
$347.00 K
|
$690.00 K
|
$1.06 M
|
$903.00 K
|
$785.00 K
|
$474.00 K
|
$168.00 K
|
| Interest Expense |
$853.00 K
|
$3.58 M
|
$0.00
|
$6.00 K
|
$0.00
|
$0.00
|
$6.00 K
|
$6.00 K
|
$11.00 K
|
$0.00
|
| Depreciation & Amortization |
$193.00 K
|
$196.00 K
|
$3.62 M
|
$77.00 K
|
$7.00 K
|
$8.00 K
|
$6.00 K
|
$5.00 K
|
$4.00 K
|
$4.00 K
|
| EBITDA |
-$14.87 M |
$7.32 M |
-$36.98 M |
-$25.04 M |
-$11.31 M |
-$14.17 M |
-$13.49 M |
-$10.76 M |
-$9.99 M |
-$7.38 M |
| EBITDA Ratio |
0
|
5.46
|
-13.68
|
-9.26
|
-4.17
|
-5.24
|
-5.51
|
-4.38
|
-15.58
|
0
|
| Operating Income Ratio |
0
|
-11.77
|
-15.02
|
-8.96
|
-4.34
|
-5.41
|
-5.52
|
-4.39
|
-15.62
|
0
|
| Total Other Income/Expenses Net |
-$3.14 M
|
$20.86 M
|
$2.93 M
|
$893.00 K
|
-$438.00 K
|
-$450.00 K
|
-$30.00 K
|
-$10.00 K
|
-$17.00 K
|
-$3.00 K
|
| Income Before Tax |
-$15.92 M
|
$5.09 M
|
-$37.66 M
|
-$22.99 M
|
-$11.51 M
|
-$14.06 M
|
-$12.73 M
|
-$10.08 M
|
-$9.63 M
|
-$7.23 M
|
| Income Before Tax Ratio |
0
|
3.8
|
-13.93
|
-8.5
|
-4.25
|
-5.2
|
-5.2
|
-4.1
|
-15.02
|
0
|
| Income Tax Expense |
$3.18 M
|
$0.00
|
$100.00 K
|
-$2.88 M
|
$192.00 K
|
$300.00 K
|
-$800.00 K
|
$400.00 K
|
$1.34 M
|
-$1.00 K
|
| Net Income |
-$19.10 M
|
$5.53 M
|
-$37.76 M
|
-$22.24 M
|
-$11.51 M
|
-$14.36 M
|
-$12.73 M
|
-$10.48 M
|
-$10.96 M
|
-$7.23 M
|
| Net Income Ratio |
0
|
4.12
|
-13.97
|
-8.23
|
-4.25
|
-5.31
|
-5.2
|
-4.27
|
-17.1
|
0
|
| EPS |
-0.47 |
0.14 |
-0.97 |
-0.78 |
-0.56 |
-0.82 |
-0.86 |
-0.79 |
-0.87 |
-0.67 |
| EPS Diluted |
-0.47 |
0.14 |
-0.97 |
-0.78 |
-0.56 |
-0.82 |
-0.86 |
-0.79 |
-0.87 |
-0.67 |
| Weighted Average Shares Out |
$40.83 M
|
$40.32 M
|
$39.00 M
|
$28.47 M
|
$20.53 M
|
$17.45 M
|
$14.88 M
|
$13.31 M
|
$12.62 M
|
$10.82 M
|
| Weighted Average Shares Out Diluted |
$40.83 M
|
$40.57 M
|
$39.00 M
|
$28.47 M
|
$20.53 M
|
$17.45 M
|
$14.88 M
|
$13.31 M
|
$12.62 M
|
$10.82 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
